Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 7 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9255085

    Carboxamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Feb 9, 2016 · Expires Feb 4, 2036

    granted
  2. US 9248132

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Feb 2, 2016 · Expires Jan 28, 2036

    granted
  3. US 9248190

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Feb 2, 2016 · Expires Jan 28, 2036

    granted
  4. US 9206161

    Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 8, 2015 · Expires Dec 3, 2035

    granted
  5. US 9181222

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Nov 10, 2015 · Expires Nov 5, 2035

    granted
  6. US 9181220

    N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Nov 10, 2015 · Expires Nov 5, 2035

    granted
  7. US 9174964

    AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same

    Rigel Pharmaceuticals, Inc. · Granted Nov 3, 2015 · Expires Oct 29, 2035

    granted
  8. US 9173882

    Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Nov 3, 2015 · Expires Oct 29, 2035

    granted
  9. US 9169249

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Oct 27, 2015 · Expires Oct 22, 2035

    granted
  10. US 9162989

    2,4-Pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Oct 20, 2015 · Expires Oct 15, 2035

    granted
  11. US 9156820

    Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 13, 2015 · Expires Oct 8, 2035

    granted
  12. US 9149475

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Oct 6, 2015 · Expires Oct 1, 2035

    granted
  13. US 9145433

    GDF-8 inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Sep 29, 2015 · Expires Sep 24, 2035

    granted
  14. US 9133133

    2,4-pyridinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted
  15. US 9096542

    Kinase inhibitors and their uses

    Rigel Pharmaceuticals, Inc. · Granted Aug 4, 2015 · Expires Jul 30, 2035

    granted
  16. US 9095593

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Aug 4, 2015 · Expires Jul 30, 2035

    granted
  17. US 9084795

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Jul 21, 2015 · Expires Jul 16, 2035

    granted
  18. US 9079898

    Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jul 14, 2015 · Expires Jul 9, 2035

    granted
  19. US 9067925

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Jun 30, 2015 · Expires Jun 25, 2035

    granted
  20. US 9062052

    Carboxamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted
  21. US 9062068

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted
  22. US 9040061

    Topical formulation for administering a compound

    Rigel Pharmaceuticals, Inc. · Granted May 26, 2015 · Expires May 21, 2035

    granted
  23. US 9040527

    Pyrimidinediamine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted May 26, 2015 · Expires May 21, 2035

    granted
  24. US 9040543

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted May 26, 2015 · Expires May 21, 2035

    granted